Agenus Inc. (Agenus) is an immuno-oncology (I-O) company. The Company focuses on the discovery and development of therapies that engage the body's immune system to fight cancer. It is developing a I-O portfolio driven by platforms and programs, such as antibody discovery platforms, including Retrocyte Display, SECANT yeast display and phage display technologies designed to produce human antibodies; antibody candidate programs, including checkpoint modulator (CPM) programs; vaccine programs, including Prophage, AutoSynVax and PhosPhoSynVax, and saponin-based vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon). The Company's discovery pipeline includes a range of checkpoint modulating (CPM) antibodies. The Company's vaccine platforms include its heat shock protein (HSP)-based Prophage vaccine candidates, and its synthetic vaccine candidates, ASV and PSV.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology & Medical Research - NEC
- Sub-Industry: Biotechnology
- Symbol: NASDAQ:AGEN
- CUSIP: 00847G70
- Web: www.agenusbio.com
Capitalization:- Market Cap: $500.55 million
- Outstanding Shares: 99,118,000
Average Prices:- 50 Day Moving Avg: $3.94
- 200 Day Moving Avg: $3.87
- 52 Week Range: $3.20 - $7.49
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -3.69
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: $43.57 million
- Price / Sales: 11.49
- Book Value: $0.09 per share
- Price / Book: 56.11
Profitability:- EBIDTA: ($85,440,000.00)
- Net Margins: -257.79%
- Return on Equity: -37,577.49%
- Return on Assets: -57.26%
Debt:- Debt-to-Equity Ratio: 15.07%
- Current Ratio: 3.80%
- Quick Ratio: 3.79%
Misc:- Average Volume: 952,648 shs.
- Beta: 2.03
- Short Ratio: 9.82
Frequently Asked Questions for Agenus (NASDAQ:AGEN)
What is Agenus' stock symbol?
Agenus trades on the NASDAQ under the ticker symbol "AGEN."
How were Agenus' earnings last quarter?
Agenus Inc. (NASDAQ:AGEN) posted its quarterly earnings data on Thursday, May, 4th. The company reported ($0.18) earnings per share for the quarter, topping analysts' consensus estimates of ($0.32) by $0.14. The company earned $26.96 million during the quarter, compared to analysts' expectations of $5.22 million. Agenus had a negative return on equity of 37,577.49% and a negative net margin of 257.79%. View Agenus' Earnings History.
When will Agenus make its next earnings announcement?
Where is Agenus' stock going? Where will Agenus' stock price be in 2017?
4 brokers have issued 1 year price targets for Agenus' shares. Their predictions range from $5.00 to $7.00. On average, they anticipate Agenus' stock price to reach $6.33 in the next year. View Analyst Ratings for Agenus.
What are analysts saying about Agenus stock?
Here are some recent quotes from research analysts about Agenus stock:
- 1. According to Zacks Investment Research, "Agenus' collaboration agreements with players like Incyte and Merck not only validate its technology platforms but also provide the company with funds. In fact, it received a boost when Merck selected its lead antibody candidate and several backup antibodies for an undisclosed checkpoint target. We are encouraged by Agenus’ efforts in developing Prophage vaccine for glioblastoma multiforme. In Mar 2017, the company undertook certain restructuring activities in order to cut costs and focus on developing key product candidates. However, with no approved product in its portfolio, Agenus is heavily dependent on collaborators for topline growth. Shares of the company have underperformed the Medical-Biomedical/Genetics industry year to date." (7/5/2017)
- 2. Maxim Group analysts commented, "Agenus reported 2Q16 with $6.6M in revenue and a net loss of $60.2M or ($0.33)." (7/28/2016)
Who are some of Agenus' key competitors?
Some companies that are related to Agenus include Immunomedics (IMMU), Cellectis S.A. (CLLS), Albany Molecular Research (AMRI), Biohaven Pharmaceutical Holding Co Ltd (BHVN), Heron Therapeutics (HRTX), TG Therapeutics (TGTX), Arena Pharmaceuticals (ARNA), Enanta Pharmaceuticals (ENTA), CRISPR THERAPTC (CRSP), Mesoblast Limited (MESO), Editas Medicine (EDIT), Spectrum Pharmaceuticals (SPPI), Intellia Therapeutics (NTLA), ANI Pharmaceuticals (ANIP), WAVE Life Sciences (WVE), ImmunoGen (IMGN), Cara Therapeutics (CARA) and Inovio Pharmaceuticals (INO).
Who are Agenus' key executives?
Agenus' management team includes the folowing people:
- Garo H. Armen Ph.D., Chairman of the Board, Chief Executive Officer, Founder
- Christine M. Klaskin, Vice President - Finance
- Karen Higgins Valentine, General Counsel, Chief Legal Officer
- Ozer Baysal, Chief Commercial Officer, Head of HR
- Jean-Marie Cuillerot M.D., Chief Medical Officer
- Brian Corvese, Independent Director
- Wadih Jordan, Independent Director
- Shalini Sharp, Independent Director
- Ulf Wiinberg, Independent Director
- Timothy R. Wright, Independent Director
Who owns Agenus stock?
Agenus' stock is owned by a number of of institutional and retail investors. Top institutional investors include Fisher Asset Management LLC (0.14%) and Quotient Investors LLC (0.05%). Company insiders that own Agenus stock include Charles Evan Ballantyne, Corp Incyte, Garo H Armen, Ozer Baysal and Ulf Wiinberg. View Institutional Ownership Trends for Agenus.
How do I buy Agenus stock?
Shares of Agenus can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Agenus' stock price today?
One share of Agenus stock can currently be purchased for approximately $5.05.
MarketBeat Community Rating for Agenus (NASDAQ AGEN)MarketBeat's community ratings are surveys of what our community members think about Agenus and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Agenus (NASDAQ:AGEN) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 1 Hold Rating, 3 Buy Ratings |
| Consensus Rating: | Buy (Score: 2.75) |
| Consensus Price Target: | $6.33 (25.41% upside) |
Analysts' Ratings History for Agenus (NASDAQ:AGEN)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 5/6/2017 | HC Wainwright | Set Price Target | Hold | $5.00 | Low |  |
| 4/23/2017 | Maxim Group | Reiterated Rating | Buy | $7.00 | Medium | |
| 12/1/2016 | JMP Securities | Reiterated Rating | Buy | | N/A | |
| 8/23/2016 | Jefferies Group LLC | Reiterated Rating | Buy | | N/A | |
| 3/9/2016 | J P Morgan Chase & Co | Lower Price Target | Market Outperform | $17.00 -> $15.00 | N/A | |
| 12/31/2015 | Oppenheimer Holdings, Inc. | Reiterated Rating | Positive -> Outperform | $14.00 | N/A | |
| 9/10/2015 | William Blair | Reiterated Rating | Buy | | N/A | |
| 7/27/2015 | MLV & Co. | Reiterated Rating | Buy | $9.00 -> $11.00 | N/A | |
(Data available from 7/23/2015 forward)
Earnings History for Agenus (NASDAQ:AGEN)Earnings History by Quarter for Agenus (NASDAQ AGEN)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 7/26/2017 | | ($0.38) | | | | | N/A | |
| 5/4/2017 | Q1 2017 | ($0.32) | ($0.18) | $5.22 million | $26.96 million | View | Listen | |
| 3/9/2017 | Q4 2016 | ($0.30) | ($0.30) | $6.01 million | $5.58 million | View | Listen | |
| 10/27/2016 | Q316 | ($0.32) | ($0.47) | $6.15 million | $4.45 million | View | Listen | |
| 7/28/2016 | Q216 | ($0.34) | ($0.33) | $5.12 million | $6.59 million | View | Listen | |
| 4/28/2016 | Q116 | ($0.23) | ($0.37) | $6.74 million | $5.96 million | View | Listen | |
| 3/3/2016 | Q415 | ($0.17) | ($0.18) | $9.39 million | $7.64 million | View | Listen | |
| 10/27/2015 | Q315 | ($0.15) | ($0.16) | $5.71 million | $6.85 million | View | Listen | |
| 7/23/2015 | Q215 | ($0.15) | ($0.44) | $5.71 million | $6.38 million | View | Listen | |
| 4/23/2015 | Q115 | ($0.15) | ($0.21) | $11.66 million | $3.95 million | View | N/A | |
| 2/26/2015 | Q414 | ($0.15) | ($0.18) | $0.66 million | $1.62 million | View | N/A | |
| 10/31/2014 | Q314 | ($0.15) | ($0.13) | $1.96 million | $1.56 million | View | N/A | |
| 7/24/2014 | Q214 | ($0.11) | ($0.12) | $0.71 million | $3.07 million | View | N/A | |
| 5/8/2014 | Q114 | ($0.16) | $0.01 | $0.55 million | $0.72 million | View | N/A | |
| 3/5/2014 | Q413 | ($0.24) | ($0.16) | $870.00 million | $393.00 million | View | N/A | |
| 10/24/2013 | Q313 | ($0.27) | ($0.24) | | $736.00 million | View | N/A | |
| 7/25/2013 | Q2 2013 | ($0.21) | ($0.40) | | | View | N/A | |
| 2/28/2013 | Q4 2012 | ($0.24) | ($0.23) | $0.72 million | $1.09 million | View | N/A | |
| 7/28/2011 | | ($0.05) | ($0.05) | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Agenus (NASDAQ:AGEN)2017 EPS Consensus Estimate: ($1.28)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 2 | ($0.33) | ($0.24) | ($0.29) |
| Q2 2017 | 2 | ($0.34) | ($0.30) | ($0.32) |
| Q3 2017 | 2 | ($0.34) | ($0.31) | ($0.33) |
| Q4 2017 | 1 | ($0.35) | ($0.35) | ($0.35) |
(Data provided by Zacks Investment Research)
Dividend History for Agenus (NASDAQ:AGEN)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Agenus (NASDAQ:AGEN)Insider Ownership Percentage: 7.60%
Institutional Ownership Percentage: 42.61%
Insider Trades by Quarter for Agenus (NASDAQ:AGEN)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 4/12/2017 | Garo H Armen | CEO | Buy | 100,000 | $3.35 | $335,000.00 | |
| 2/14/2017 | Corp Incyte | Major Shareholder | Buy | 10,000,000 | $6.00 | $60,000,000.00 | |
| 9/6/2016 | Ulf Wiinberg | Director | Buy | 30,000 | $6.29 | $188,700.00 | |
| 5/9/2016 | Garo H Armen | CEO | Buy | 100,000 | $3.18 | $318,000.00 | |
| 5/5/2016 | Ozer Baysal | Insider | Buy | 2,250 | $3.10 | $6,975.00 | |
| 3/7/2016 | Garo H Armen | CEO | Buy | 200,000 | $4.03 | $806,000.00 | |
| 12/29/2015 | Garo H. Armen | CEO | Sell | 219,576 | $4.59 | $1,007,853.84 | |
| 12/28/2015 | Garo H. Armen | CEO | Sell | 134,352 | $4.60 | $618,019.20 | |
| 9/25/2015 | Charles Evan Ballantyne | CFO | Buy | 10,000 | $5.05 | $50,500.00 | |
| 9/25/2015 | Garo H Armen | CEO | Buy | 100,000 | $5.03 | $503,000.00 | |
| 4/29/2015 | Shahzad Malik | Director | Sell | 1,107,377 | $7.11 | $7,873,450.47 | |
| 1/9/2015 | Qvt Associates Gp Llc | Major Shareholder | Sell | 2,343,630 | $5.31 | $12,444,675.30 | |
| 1/23/2014 | Karen Valentine | VP | Sell | 2,850 | $3.50 | $9,975.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Agenus (NASDAQ:AGEN)
Latest Headlines for Agenus (NASDAQ:AGEN)
| Source: |
|
| Date | Headline |
|---|
 | Is a Beat in Store for Alexion (ALXN) this Earnings Season?
www.nasdaq.com - July 20 at 4:16 PM |
 | uniQure N.V. (QURE) Shows Strength: Stock Moves 9.1% Higher
finance.yahoo.com - July 20 at 4:16 PM |
| Agenus (AGEN) Catches Eye: Stock Moves Up 8.7% in Session
finance.yahoo.com - July 19 at 4:24 PM |
 | Agenus Inc. (NASDAQ:AGEN) Scheduled to Post Quarterly Earnings on Wednesday
www.americanbankingnews.com - July 19 at 9:00 AM |
 | Agenus breaks out of brief consolidation after Glaxo shingles vaccine data-stoked up move; shares ahead 9%
seekingalpha.com - July 10 at 4:20 PM |
| Agenus Inc. (NASDAQ:AGEN) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - July 10 at 11:14 AM |
| Agenus Inc. (AGEN) Cut to "Strong Sell" at ValuEngine
www.americanbankingnews.com - July 8 at 10:52 PM |
| Alexion Reportedly Being Investigated by HHS, Shares Slip
finance.yahoo.com - July 7 at 5:21 PM |
| Geron Stock Up Almost 40% So Far This Year After '16 Decline
finance.yahoo.com - July 5 at 4:03 PM |
| Agenus Inc. (AGEN) Rating Increased to Buy at Zacks Investment Research
www.americanbankingnews.com - July 5 at 2:06 PM |
| Is the Options Market Predicting a Spike in Agenus (AGEN) Stock? - Nasdaq
www.nasdaq.com - July 3 at 3:31 PM |
 | Better Buy: Agenus Inc. vs. Kite Pharma - Motley Fool
www.fool.com - July 3 at 3:31 PM |
| Is the Options Market Predicting a Spike in Agenus (AGEN) Stock?
finance.yahoo.com - July 3 at 3:31 PM |
 | Glioblastoma Multiforme Pipeline Therapeutics and Drug Profiles Analysis 2017 - RnR Market Research
www.prnewswire.com - July 3 at 6:22 AM |
| Better Buy: Agenus Inc. vs. Kite Pharma
www.fool.com - July 2 at 8:11 AM |
| These Two Biotech Stocks Could Move On Near Term Vaccine Catalysts
seekingalpha.com - June 30 at 3:40 PM |
| Zacks: Analysts Expect Agenus Inc. (AGEN) Will Announce Quarterly Sales of $5.29 Million
www.americanbankingnews.com - June 30 at 2:31 PM |
| FY2021 Earnings Forecast for Agenus Inc. (AGEN) Issued By William Blair
www.americanbankingnews.com - June 29 at 1:34 PM |
| -$0.38 EPS Expected for Agenus Inc. (AGEN) This Quarter
www.americanbankingnews.com - June 28 at 8:28 AM |
| Q2 2017 EPS Estimates for Agenus Inc. (AGEN) Increased by William Blair
www.americanbankingnews.com - June 28 at 7:36 AM |
| Agenus Inc. (AGEN) Expected to Post FY2020 Earnings of ($1.17) Per Share
www.americanbankingnews.com - June 27 at 3:26 PM |
| Agenus to Webcast Annual Meeting of Stockholders - PR Newswire (press release)
www.prnewswire.com - June 21 at 4:07 PM |
| Positive Phase 3 for GSK's shingles vaccine Shingrix with Agenus' QS-21 Stimulon® immune adjuvant - PR Newswire (press release)
www.prnewswire.com - June 21 at 4:07 PM |
| Agenus, Inc. breached its 50 day moving average in a Bullish Manner : AGEN-US : June 21, 2017
finance.yahoo.com - June 21 at 4:07 PM |
| Agenus (AGEN) Looks Good: Stock Moves Up 9.6% in Session
finance.yahoo.com - June 21 at 4:07 PM |
| Agenus to Webcast Annual Meeting of Stockholders
finance.yahoo.com - June 21 at 4:07 PM |
| Positive Phase 3 for GSK's shingles vaccine Shingrix with Agenus' QS-21 Stimulon® immune adjuvant
finance.yahoo.com - June 21 at 4:07 PM |
| GSK presents positive results from Phase III revaccination study of its candidate shingles vaccine Shingrix at CDC's Advisory Meeting
finance.yahoo.com - June 21 at 4:07 PM |
| Agenus (AGEN) Down 15.7% Since Earnings Report: Can It ... - Nasdaq
www.nasdaq.com - June 8 at 3:30 PM |
| Agenus (AGEN) Down 15.7% Since Earnings Report: Can It Rebound?
finance.yahoo.com - June 8 at 3:30 PM |
| Agenus' anti-CTLA-4 antibody shows strong safety and tolerability - PR Newswire (press release)
www.prnewswire.com - June 6 at 10:33 AM |
| Agenus' anti-CTLA-4 antibody shows strong safety and tolerability
finance.yahoo.com - June 5 at 1:33 PM |
| Brokerages Anticipate Agenus Inc (AGEN) Will Post Quarterly Sales of $5.19 Million
www.americanbankingnews.com - June 4 at 9:50 AM |
| -$0.39 Earnings Per Share Expected for Agenus Inc (AGEN) This Quarter
www.americanbankingnews.com - June 2 at 7:34 AM |
| Agenus to Participate at Two Upcoming Conferences in New York ... - PR Newswire (press release)
www.prnewswire.com - June 1 at 3:33 PM |
| Agenus to Participate at Two Upcoming Conferences in New York City: Jefferies Healthcare and JMP Securities Life Sciences
finance.yahoo.com - June 1 at 3:33 PM |
| Noteworthy Tuesday Option Activity: GOOG, PANW, AGEN
www.nasdaq.com - May 30 at 3:30 PM |
| Agenus to present safety results for anti-CTLA-4 antibody at ASCO ... - PR Newswire (press release)
www.prnewswire.com - May 22 at 3:24 PM |
| Agenus to present safety results for anti-CTLA-4 antibody at ASCO 2017 Annual Meeting
finance.yahoo.com - May 22 at 3:24 PM |
| ETFs with exposure to Agenus, Inc. : May 22, 2017
finance.yahoo.com - May 22 at 3:24 PM |
| Research Reports Initiation on Biotech Stocks -- Agenus, Athersys ... - PR Newswire (press release)
www.prnewswire.com - May 19 at 3:24 PM |
| ETFs with exposure to Agenus, Inc. : May 11, 2017
finance.yahoo.com - May 11 at 8:48 PM |
| $5.19 Million in Sales Expected for Agenus Inc (AGEN) This Quarter
www.americanbankingnews.com - May 10 at 9:16 AM |
| Agenus, Inc. :AGEN-US: Earnings Analysis: Q1, 2017 By the Numbers : May 9, 2017
finance.yahoo.com - May 9 at 3:23 PM |
| Brokerages Anticipate Agenus Inc (AGEN) Will Announce Earnings of -$0.31 Per Share
www.americanbankingnews.com - May 8 at 10:27 PM |
| Agenus, Inc. – Value Analysis (NASDAQ:AGEN) : May 8, 2017
finance.yahoo.com - May 8 at 8:47 PM |
 | Agenus Stock Bounces on Q1 Report, Update
www.baystreet.ca - May 5 at 8:25 PM |
| Agenus Inc (AGEN) Announces Quarterly Earnings Results
www.americanbankingnews.com - May 5 at 3:58 PM |
| Agenus (AGEN) Reports Narrower-than-Expected Loss in Q1 - Nasdaq
www.nasdaq.com - May 5 at 3:24 PM |
| Agenus, Inc. breached its 50 day moving average in a Bullish Manner : AGEN-US : May 5, 2017
finance.yahoo.com - May 5 at 3:24 PM |
Agenus (AGEN) Chart for Sunday, July, 23, 2017
